More than 50 years ago patients with sickle cell anemia surviving to adulthood with few acute painful events were deemed "mild" or "relatively benign." 1,2 Their clinical course contrasted with the dismal prospects of this disease in Africa where death in childhood was and remains common. 3 Early descriptions of "mild" disease where acute episodes did not dominate the clinical course failed to consider the pathophysiology of sub-phenotypes other than acute painful episodes. These include cerebrovascular disease, neurocognitive deficits, chronic renal disease, pulmonary vasculopathy, and diastolic heart dysfunction. Except for stroke, these sub-phenotypes tend to be silent, especially in their earliest stages, but have a large effect on adult mortality and morbidity. 4,5 Chronic intravascular hemolysis of sickle hemoglobin (HbS) polymer-damaged erythrocytes along with chronic vasoocclusion with ischemia-reperfusion injury liberates hemoglobin and heme into the circulation depleting bioavailable nitric oxide producing a proliferative vasculopathy. [6][7][8] (Figure 1). Adulthood in sickle cell anemia brings progressive end-organ damage, impaired quality of life, and high mortality rates-even in high-resourced countries. With choices of disease-modifying treatments available, including poly-pharmaceutical regimens or cell-based therapeutics like allogeneic transplantation and perhaps soon, gene therapy, grading disease "severity" and intuiting its likely trajectory become important. However, patients, physicians, and clinical investigators can view differently the "severity" of adult sickle cell anemia.Three examples are illustrative.